Analytical Data
-
Gene name
DAT
- Application
-
Alternative Names
SLC6A3; DAT1; Sodium-dependent dopamine transporter; Dopamine Active Transporter; SLC6-A3; Solute Carrier Family 6(neurotransmitter Transporter,Dopamine),Member 3
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q01959
-
Expression Region
Trp562~Val620
-
Molecular Weight
37kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Dopamine transporter (DAT) is a critical protein involved in the reuptake of dopamine from the synaptic cleft into presynaptic neurons, playing an essential role in regulating dopamine signaling in the brain. Abnormalities in DAT function are linked to various neurological and psychiatric disorders, including Parkinson's disease, attention deficit hyperactivity disorder (ADHD), and substance use disorders. Researchers have focused on recombinant DAT proteins to better understand their structure, function, and interactions with ligands, including drugs that target dopamine receptors. This research has implications for drug development and the treatment of dopaminergic dysfunctions. Structural studies involving X-ray crystallography and cryo-electron microscopy have provided insights into the conformational dynamics of DAT and its binding sites, shedding light on how different substances modulate its activity. Additionally, the use of recombinant techniques allows for the production of DAT variants to study specific mutations and their effects on transporter function. Overall, the investigation of DAT and its recombinant forms is crucial for elucidating the molecular mechanisms of dopamine transport and developing therapeutic strategies for dopamine-related disorders.
